SOMAXON PHARMACEUTICALS
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.
SOMAXON PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Solana Beach, California, United States
Country:
United States
Website Url:
http://www.somaxon.com
Total Employee:
251+
Status:
Active
Contact:
858-876-6500
Email Addresses:
[email protected]
Total Funding:
94 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Nginx Euro
Similar Organizations
Pacira Pharmaceuticals
Pacira Pharmaceuticals is a specialty pharmaceutical company dedicated to postsurgical innovation.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Prospect Venture Partners
Prospect Venture Partners investment in Post-IPO Equity - Somaxon Pharmaceuticals
MPM Capital
MPM Capital investment in Post-IPO Equity - Somaxon Pharmaceuticals
Domain Associates
Domain Associates investment in Post-IPO Equity - Somaxon Pharmaceuticals
Tavistock Life Sciences
Tavistock Life Sciences investment in Post-IPO Equity - Somaxon Pharmaceuticals
Scale Venture Partners
Scale Venture Partners investment in Post-IPO Equity - Somaxon Pharmaceuticals
Montreux Equity Partners
Montreux Equity Partners investment in Post-IPO Equity - Somaxon Pharmaceuticals
Prospect Venture Partners
Prospect Venture Partners investment in Series C - Somaxon Pharmaceuticals
MPM Capital
MPM Capital investment in Series C - Somaxon Pharmaceuticals
Domain Associates
Domain Associates investment in Series C - Somaxon Pharmaceuticals
CDIB BioScience Ventures
CDIB BioScience Ventures investment in Series C - Somaxon Pharmaceuticals
Official Site Inspections
http://www.somaxon.com
- Host name: 173-198-247-252.static.as40244.net
- IP address: 173.198.247.252
- Location: Latham United States
- Latitude: 42.747
- Longitude: -73.7527
- Metro Code: 532
- Timezone: America/New_York
- Postal: 12110
More informations about "Somaxon Pharmaceuticals"
Somaxon Pharmaceuticals - Crunchbase Company Profile & Funding
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical …See details»
Somaxon Pharmaceuticals - Funding, Financials, Valuation
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription. New. Resources. ... How much funding has …See details»
Somaxon – Feel Health & Beautiful Again
Dec 18, 2024 Their job is to ensure that laser systems are safe by getting involved at all levels of the organization and ensuring compliance with the regulations. Photodynamic Therapy. …See details»
Somaxon Pharmaceuticals Inc. - life-sciences-usa.com
Aug 1, 2003 Somaxon Pharmaceuticals Inc. https://www.somaxon.com Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on …See details»
Somaxon Pharmaceuticals - Products, Competitors, Financials, …
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates …See details»
Somaxon Pharmaceuticals, Inc. : Shareholders Board Members …
Somaxon Pharmaceuticals, Inc. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: | NasdaqSee details»
Somaxon Pharmaceuticals, Inc. (Form: S-8, Filing Date: 04/15/2011)
SOMAXON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20 161599 (State or other jurisdiction of incorporation or organization) (I.R.S. …See details»
SOMAXON PHARMACEUTICALS Canadian Trademark Information
SOMAXON PHARMACEUTICALS is a canadian trademark and brand of PERNIX SLEEP, INC., Morristown, NJ 07960,UNITED STATES. This trademark was filed to the Canadian Intellectual …See details»
SOMAXON PHARMACEUTICALS REPORTS THIRD QUARTER 2010 …
Nov 11, 2010 On September 20, 2010, full-scale, field-based promotion of Silenor began with the deployment of Somaxon's 110 sales representatives (provided by Somaxon's contract …See details»
Somaxon Pharmaceuticals, Inc. (Somaxon Pharmaceuticals, Inc.)
了解Somaxon Pharmaceuticals, Inc. (Somaxon Pharmaceuticals, Inc.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 6篇新闻和1篇文献，药物:盐酸纳美芬。See details»
Somaxon Healthcare Private Limited | Company Details - The …
Dec 20, 2024 Somaxon Healthcare Private Limited (SHPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 October 2023 (One year and four months …See details»
Somaxon Definition - Law Insider
Define Somaxon. has the meaning set forth in the Preamble of this Agreement.See details»
Somaxon Pharmaceuticals Appoints Chief Financial Officer and …
Apr 14, 2010 Somaxon Pharmaceuticals Appoints Chief Financial Officer and Announces Senior Leadership Promotions SAN DIEGO--(BUSINESS WIRE)--Apr 12, 2010 - Somaxon …See details»
C&L: Patheon keeps Trecroce as CEO - Fierce Biotech
Apr 3, 2007 Patheon has named Riccardo Trecroce as CEO. He was initially appointed as CEO for an interim period in September 2006. Somaxon Pharmaceuticals has named James …See details»
Paladin to commercialise Somaxon’s Silenor in select markets …
Under the terms of the deal, Somaxon will receive an up-front payment of $500 000 and Paladin will purchase just over 2.1 million shares of Somaxon's common stock at a price of $5 million. …See details»
Somaxon, P&G to co-promote Silenor | Drug Store News
Aug 30, 2010 The term of the agreement runs through Dec. 31, 2012, renewable thereafter, and Somaxon will pay P&G a reduced royalty based on U.S. net sales of Silenor for one year after …See details»
Somaxon NDA Definition - Law Insider
Define Somaxon NDA. means NDA No. 22-036, including all supplements and amendments thereto.See details»
Somaxon Pharmaceuticals, Inc. v. Par Pharmaceutical - Casetext
Jul 28, 2011 3. Par is interested in producing a generic version of Silenor® and was the third filer of an ANDA for approval to manufacture and market a generic verison of Silenor®. (D.I. 20 at …See details»
Somaxon (finally) wins FDA approval for sleep drug Silenor
Mar 18, 2010 San Diego-based Somaxon has won FDA approval of its sleep drug Silenor, completing a long and financially exhausting quest that has consumed more than $170 million. …See details»
Transgene plans to raise more than $200M; GW shares spike on …
Mar 23, 2010 > Somaxon says it plans to raise up to $35 million from a stock sale and plans to use the money to start marketing the newly approved Silenor. StorySee details»